Banco Santander S.A. Decreases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Banco Santander S.A. trimmed its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 54.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 172,231 shares of the biopharmaceutical company’s stock after selling 205,137 shares during the period. Banco Santander S.A. owned about 0.11% of Ocular Therapeutix worth $1,498,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Deltec Asset Management LLC increased its stake in Ocular Therapeutix by 9.6% in the second quarter. Deltec Asset Management LLC now owns 2,590,265 shares of the biopharmaceutical company’s stock valued at $17,717,000 after purchasing an additional 226,181 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Ocular Therapeutix by 1,142.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 662,672 shares of the biopharmaceutical company’s stock valued at $6,031,000 after buying an additional 609,328 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Ocular Therapeutix by 41.4% in the first quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock valued at $65,840,000 after acquiring an additional 2,117,029 shares during the period. Cetera Advisors LLC increased its holdings in shares of Ocular Therapeutix by 1,455.0% in the 1st quarter. Cetera Advisors LLC now owns 723,490 shares of the biopharmaceutical company’s stock valued at $6,584,000 after acquiring an additional 676,963 shares during the period. Finally, Rhumbline Advisers boosted its stake in Ocular Therapeutix by 39.1% during the 2nd quarter. Rhumbline Advisers now owns 211,301 shares of the biopharmaceutical company’s stock worth $1,445,000 after purchasing an additional 59,345 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the stock. HC Wainwright lifted their price objective on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Robert W. Baird reduced their price objective on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Finally, Scotiabank began coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 target price on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Ocular Therapeutix Stock Performance

NASDAQ OCUL opened at $8.83 on Friday. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $9.90 and its two-hundred day moving average is $8.09. Ocular Therapeutix, Inc. has a 12-month low of $2.14 and a 12-month high of $11.77.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.